1266348-03-1

Upstream product

• 1424337-16-5 3-(3-(1,3-dioxoisoindolin-2-yl)propoxy)-4-methoxybenzaldehyde 
• 1424337-20-1 3-(3-(1,3-dioxoisoindolin-2-yl)propoxy)-4-methoxybenzoic acid 
• 1185160-66-0 3-(3-chloropropox y)-N-(3,5-dichloropyridin-4-yl) - 4-methoxybenzamine 
• 645-08-9 Isovanillic acid 

Downstream Products

• 1266348-04-2 C₅₈H₈₄Cl₂N₄O₁₈ 
• 1266348-05-3 C₅₄H₈₀Cl₂N₄O₁₆ 
• 1424337-27-8 3-(3-(2-(tert-butyldimethylsilyloxy)-2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethylamino)propoxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide 
• 1424337-09-6 C₂₅H₂₇Cl₂N₃O₆ 

Relevant academic research and scientific papers

Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD

A novel class of dual pharmacology bronchodilators targeting both β2-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone. All the compounds exhibited better β2-adrenoceptor agonist activities (pEC50 = 8.47-9.20) than the reference compound salmeterol (pEC50 = 8.3) and good inhibitory activity on PDE4B2 (IC 50 = 0.235-1.093 μM).

NEW MACROLIDES AND THEIR USE

The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to proces